{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T13:53:58Z","timestamp":1774619638148,"version":"3.50.1"},"reference-count":45,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T00:00:00Z","timestamp":1563840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001316","name":"Abbott Laboratories","doi-asserted-by":"publisher","award":["Unknown"],"award-info":[{"award-number":["Unknown"]}],"id":[{"id":"10.13039\/100001316","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008568","name":"Norske Kvinners Sanitetsforening","doi-asserted-by":"publisher","award":["14902"],"award-info":[{"award-number":["14902"]}],"id":[{"id":"10.13039\/501100008568","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0220079","type":"journal-article","created":{"date-parts":[[2019,7,23]],"date-time":"2019-07-23T17:31:51Z","timestamp":1563903111000},"page":"e0220079","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":20,"title":["Tumor necrosis factor inhibitors are associated with reduced complement activation in spondylarthropathies: An observational study"],"prefix":"10.1371","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8009-4670","authenticated-orcid":true,"given":"Ingrid","family":"Hokstad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gia","family":"Deyab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten","family":"Wang Fagerland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Torstein","family":"Lyberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gunnbj\u00f8rg","family":"Hjeltnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d8ystein","family":"F\u00f8rre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Agewall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom Eirik","family":"Mollnes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Hollan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,7,23]]},"reference":[{"issue":"12","key":"ref1","first-page":"773","article-title":"Atherosclerosis in psoriatic arthritis","volume":"10","author":"R Ramonda","year":"2011","journal-title":"AutoimmunRev"},{"issue":"2","key":"ref2","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/ard.2009.113696","article-title":"EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis","volume":"69","author":"MJ Peters","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"ref3","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.semarthrit.2004.07.010","article-title":"Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis","volume":"34","author":"MJ Peters","year":"2004","journal-title":"Semin Rheum"},{"issue":"4","key":"ref4","first-page":"358","article-title":"Cardiovascular risks in spondyloarthritides","volume":"19","author":"S Heeneman","year":"2007","journal-title":"CurrOpinRheumatol"},{"issue":"6917","key":"ref5","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/nature01323","article-title":"Inflammation in atherosclerosis","volume":"420","author":"P Libby","year":"2002","journal-title":"Nature"},{"issue":"1","key":"ref6","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11882-014-0489-6","article-title":"Update on ankylosing spondylitis: current concepts in pathogenesis","volume":"15","author":"JA Smith","year":"2015","journal-title":"Curr Allergy Asthma Rep"},{"issue":"2","key":"ref7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.molimm.2014.06.031","article-title":"The complement system in human cardiometabolic disease","volume":"61","author":"E Hertle","year":"2014","journal-title":"Mol Immunol"},{"issue":"8","key":"ref8","doi-asserted-by":"crossref","first-page":"3831","DOI":"10.4049\/jimmunol.1203487","article-title":"Complement in immune and inflammatory disorders: pathophysiological mechanisms","volume":"190","author":"D Ricklin","year":"2013","journal-title":"J Immunol"},{"issue":"8","key":"ref9","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1038\/nrrheum.2012.75","article-title":"Complement in the immunopathogenesis of rheumatic disease","volume":"8","author":"G Sturfelt","year":"2012","journal-title":"Nat Rev Rheumatol"},{"key":"ref10","first-page":"1","article-title":"Parren PWHI. Complement in therapy and disease","author":"JPM Melis","year":"2015","journal-title":"Mol Immunol"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/imm.12556","article-title":"Complementing the inflammasome","volume":"147","author":"M Triantafilou","year":"2016","journal-title":"Immunology"},{"issue":"3","key":"ref12","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2009.11.014","article-title":"The complement system in systemic autoimmune disease","volume":"34","author":"M Chen","year":"2010","journal-title":"J Autoimmun"},{"key":"ref13","first-page":"402783","article-title":"Complement activation: an emerging player in the pathogenesis of cardiovascular disease","volume":"2012","author":"AM Carter","year":"2012","journal-title":"Scientifica (Cairo)"},{"issue":"5","key":"ref14","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.ahj.2012.08.018","article-title":"Soluble form of membrane attack complex independently predicts mortality and cardiovascular events in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention","volume":"164","author":"S Lindberg","year":"2012","journal-title":"Am Heart J"},{"issue":"5","key":"ref15","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.molimm.2009.10.035","article-title":"The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice","volume":"47","author":"RD Lewis","year":"2010","journal-title":"Mol Immunol"},{"issue":"12","key":"ref16","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrrheum.2015.112","article-title":"Cardiovascular comorbidity in rheumatic diseases","volume":"11","author":"MT Nurmohamed","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"2","key":"ref17","doi-asserted-by":"crossref","first-page":"e0169830","DOI":"10.1371\/journal.pone.0169830","article-title":"Anti-rheumatic treatment is not associated with reduction of pentraxin 3 in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis","volume":"12","author":"G Deyab","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"ref18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.molimm.2013.05.221","article-title":"An international serum standard for application in assays to detect human complement activation products","volume":"56","author":"G Bergseth","year":"2013","journal-title":"Mol Immunol"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.jacc.2004.08.062","article-title":"Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia","volume":"44","author":"PO Bonetti","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"ref20","first-page":"250","article-title":"Terminal complement complexes and C1\/C1 inhibitor complexes in rheumatoid arthritis and other arthritic conditions","volume":"84","author":"DA Oleesky","year":"1991","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"ref21","first-page":"225","article-title":"Impaired expression of erythrocyte glycosyl-phosphatidylinositol-anchored membrane CD59 in patients with psoriatic arthritis. Relation to terminal complement pathway activation","volume":"21","author":"G Triolo","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"ref22","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1002\/art.10183","article-title":"Local production of complement proteins in rheumatoid arthritis synovium","volume":"46","author":"E Neumann","year":"2002","journal-title":"Arthritis Rheum"},{"issue":"12","key":"ref23","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1002\/art.1780341209","article-title":"Synovial fluid levels of complement SC5b-9 and fragment Bb are elevated in patients with rheumatoid arthritis","volume":"34","author":"JP Brodeur","year":"1991","journal-title":"Arthritis Rheum"},{"issue":"10","key":"ref24","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1080\/00365520310005767","article-title":"Complement activation in plasma before and after infliximab treatment in Crohn disease","volume":"38","author":"E Zimmermann-Nielsen","year":"2003","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"ref25","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2004.029124","article-title":"Infliximab treatment reduces complement activation in patients with rheumatoid arthritis","volume":"64","author":"A Familian","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"ref26","first-page":"23","article-title":"Complement system in psoriatic arthritis: a useful marker in response prediction and monitoring of anti-TNF treatment","volume":"30","author":"MS Chimenti","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"ref27","doi-asserted-by":"crossref","first-page":"e0162316","DOI":"10.1371\/journal.pone.0162316","article-title":"Anti-Drug Antibodies, Drug Levels, Interleukin-6 and Soluble TNF Receptors in Rheumatoid Arthritis Patients during the First 6 Months of Treatment with Adalimumab or Infliximab: A Descriptive Cohort Study","volume":"11","author":"GP Eng","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1373\/clinchem.2008.119214","article-title":"C-Reactive Protein: Eighty Years from Discovery to Emergence as a Major Risk Marker for Cardiovascular Disease","volume":"55","author":"PM Ridker","year":"2008","journal-title":"Clin Chem"},{"issue":"5","key":"ref29","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1172\/JCI112721","article-title":"Cachectin\/tumor necrosis factor regulates hepatic acute-phase gene expression","volume":"78","author":"DH Perlmutter","year":"1986","journal-title":"J Clin Invest"},{"issue":"6","key":"ref30","first-page":"S76","article-title":"Methotrexate in psoriatic arthritis","volume":"20","author":"M Cutolo","journal-title":"Clin Exp Rheumatol"},{"key":"ref31","article-title":"Low-Dose Methotrexate for the Prevention of Atherosclerotic Events\u2014CIRT","author":"PM Ridker","year":"2018","journal-title":"N Engl J Med"},{"key":"ref32","article-title":"Complement activation products C5a and sC5b-9 are associated with low-grade inflammation and endothelial dysfunction, but not with atherosclerosis \u2026\u2014PubMed\u2014NCBI","year":"2014","journal-title":"Int J Cardiol"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1536\/ihj.14-385","article-title":"Assessment of endothelial function. History, methodological aspects, and clinical perspectives","volume":"56","author":"Y Higashi","year":"2015","journal-title":"Int Heart J"},{"issue":"6","key":"ref34","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1161\/CIRCULATIONAHA.112.093245","article-title":"The assessment of endothelial function: from research into clinical practice","volume":"126","author":"AJ Flammer","year":"2012","journal-title":"Circulation"},{"issue":"11","key":"ref35","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1016\/j.jacc.2004.08.062","article-title":"Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia","volume":"44","author":"PO Bonetti","year":"2004","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"ref36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/00004872-200501000-00004","article-title":"Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension","volume":"23","author":"J Deanfield","year":"2005","journal-title":"J Hypertens"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.thromres.2007.11.005","article-title":"Regulated complement deposition on the surface of human endothelial cells: Effect of tobacco smoke and shear stress","volume":"122","author":"W Yin","year":"2008","journal-title":"Thromb Res"},{"issue":"4","key":"ref38","doi-asserted-by":"crossref","first-page":"L254","DOI":"10.1152\/ajplung.1991.260.4.L254","article-title":"Complement activation by cigarette smoke","volume":"260","author":"RA Robbins","year":"1991","journal-title":"Am J Physiol Cell Mol Physiol"},{"issue":"3","key":"ref39","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1172\/JCI111760","article-title":"Cigarette smoke can activate the alternative pathway of complement in vitro by modifying the third component of complement","volume":"75","author":"RR Kew","year":"1985","journal-title":"J Clin Invest"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s102380200004","article-title":"Relationship between serum complement and different lipid disorders","volume":"2","author":"AL Pasqui","year":"2002","journal-title":"Clin Exp Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1007\/978-3-319-09665-0_14","article-title":"Impact of systemic inflammation and autoimmune diseases on apoA-I and HDL plasma levels and functions","volume":"224","author":"F Montecucco","year":"2015","journal-title":"Handb Exp Pharmacol"},{"issue":"5","key":"ref42","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1002\/art.24492","article-title":"Improvement of lipid profile is accompanied by atheroprotective alterations in high-density lipoprotein composition upon tumor necrosis factor blockade: A prospective cohort study in ankylosing spondylitis","volume":"60","author":"IC Van Eijk","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"5","key":"ref43","doi-asserted-by":"crossref","first-page":"3632","DOI":"10.1016\/S0021-9258(18)53740-6","article-title":"Interaction between apolipoproteins A-I and A-II and the membrane attack complex of complement. Affinity of the apoproteins for polymeric C9","volume":"268","author":"KK Hamilton","year":"1993","journal-title":"J Biol Chem"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.atherosclerosis.2016.11.015","article-title":"High density lipoproteins are modulators of protease activity: Implications in inflammation, complement activation, and atherothrombosis","volume":"259","author":"SM Gordon","year":"2017","journal-title":"Atherosclerosis"},{"issue":"3","key":"ref45","first-page":"341","article-title":"Observational versus experimental studies: what\u2019s the evidence for a hierarchy? NeuroRx","volume":"1","author":"J Concato","year":"2004","journal-title":"Am. Soc."}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0220079","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T02:33:14Z","timestamp":1610591594000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0220079"}},"subtitle":[],"editor":[{"given":"Yoshishige","family":"Miyabe","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,7,23]]},"references-count":45,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2019,7,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0220079","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,23]]}}}